Abstract
The metabolic state of T cells strongly influences their effector function and anti-tumor efficacy. St. Paul et al. (2021) report that Tc22, a CD8+ T cell subset with potent anti-tumor activity, upregulates the pantothenate/coenzyme A (CoA) pathway and that treatment with CoA or pantothenate is sufficient to enhance tumor immunotherapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2305-2306 |
| Number of pages | 2 |
| Journal | Cell Metabolism |
| Volume | 33 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 7 2021 |
Bibliographical note
Publisher Copyright:© 2021 Elsevier Inc.
PubMed: MeSH publication types
- Journal Article
- Comment
Fingerprint
Dive into the research topics of 'CoAching CD8+ T cells for tumor immunotherapy—the pantothenate way'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS